US Stock MarketDetailed Quotes
SAGE Sage Therapeutics
- 10.380
- -2.700-20.64%
Close Jul 24 16:00 ET
- 10.625
- +0.245+2.36%
Post 16:56 ET
624.69MMarket Cap-1237P/E (TTM)
11.090High9.810Low2.62MVolume10.080Open13.080Pre Close27.47MTurnover5.51%Turnover RatioLossP/E (Static)60.18MShares37.16552wk High0.89P/B493.23MFloat Cap9.76052wk Low--Dividend TTM47.52MShs Float195.970Historical High--Div YieldTTM9.78%Amplitude9.760Historical Low10.487Avg Price1Lot Size
Sage Therapeutics Stock Forum
Sign in to post a comment
$Sage Therapeutics(SAGE.US$ Sage Therapeutics Inc: Sage-324 (Biib124) Did Not Demonstrate a Statistically Significant Dose-Response Relationship on Primary Endpoint
4
$Sage Therapeutics(SAGE.US$ what just happened
$Sage Therapeutics(SAGE.US$ what’s happening
1
$Sage Therapeutics(SAGE.US$ Sage Therapeutics Says Phase 2 SURVEYOR Study Strengthens Cognitive Impact Of Huntington's Disease! For Participants With Hd Got Dalzanemdor or Placebo, Dalzanemdor Was Generally Well-Tolerated With No New Safety Signals Observed
1
Pre-Market Stock Movers
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
Gapping up
$Salesforce(CRM.US$ jumped 6.2% following its earnings beat after the bell Wednesday. Adjusted earnings per share came in at $2.12 for the second quarter, versus the consensus estimate of $1.90, per Refinitiv. Revenue was $8.60 billion, topping the $8.53 expected. Goldman Sachs subsequently hiked its price target by $15 to $340 a share, suggestions 58% upside.
$UBS Group(UBS.US$ popp...
24
1
$Apellis Pharmaceuticals(APLS.US$ $Alteryx(AYX.US$ $Barfresh Food(BRFH.US$ $Celanese Corp(CE.US$ $Chegg(CHGG.US$ $Chewy(CHWY.US$ $Extra Space Storage Inc(EXR.US$ $Five9(FIVN.US$ $International Flavors & Fragrances(IFF.US$ $Lucid Group(LCID.US$ $Paramount Global-B(PARA.US$ $Sage Therapeutics(SAGE.US$ $ShockWave Medical(SWAV.US$ $Teradata Corp(TDC.US$ $VistaGen Therapeutics(VTGN.US$ $Wynn Resorts(WYNN.US$
follow for daily watchlist 🚀
follow for daily watchlist 🚀
3
$Sage Therapeutics(SAGE.US$
Great entry point. As long as it is approved and on the market, it will be open for off-label use for MDD if someone really wants it.
Great entry point. As long as it is approved and on the market, it will be open for off-label use for MDD if someone really wants it.
1
$Sage Therapeutics(SAGE.US$ the medicine got approval as a quick fix for PPD 产后抑郁症 after delivery. It can make some big money for that. Sorry but women have many troubles after delivery. Well done.
However MDD 一般抑郁症 is not approved. Although they are not serious enough for MDD. MDD means huge money. And people with MDD typically take pills for years. Guess what, wall street and elites, they know mental health better than you
Now no huge money but just big mon...
However MDD 一般抑郁症 is not approved. Although they are not serious enough for MDD. MDD means huge money. And people with MDD typically take pills for years. Guess what, wall street and elites, they know mental health better than you
Now no huge money but just big mon...
2
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
TrytosaveabitOP : Sage Therapeutics Inc: Do Not Plan to Conduct Further Clinical Development of Sage-324 in Et
买跌不追涨 : Can't go short
TrytosaveabitOP 买跌不追涨: Sorry. I won’t go short. Don’t believe in it personally! GL
买跌不追涨 TrytosaveabitOP: I also seldom go short